Quality of life in HIV clinical trials: Why sexual health must not be ignored

PLoS Clinical Trials

Volumn 2, Issue 3, 2007, Pages

  Koole, Oliver ^a   Noestlinger, Christiana ^a   Colebunders, Robert ^a,b  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ARTICLE; CLINICAL RESEARCH; DRUG MARKETING; DRUG PREFERENCE; DYSPAREUNIA; ERECTILE DYSFUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIBIDO DISORDER; MALE HOMOSEXUAL; OFF LABEL DRUG USE; ORGASM DISORDER; PATIENT COMPLIANCE; PUBLIC HEALTH; QUALITY OF LIFE; QUESTIONNAIRE; SAFE SEX; SEXUAL AROUSAL DISORDER; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUAL HEALTH; SHORT FORM 36; VIRUS INHIBITION; VIRUS LOAD;

EID: 34249796677     PISSN: None     EISSN: 15555887     Source Type: Journal    
DOI: 10.1371/journal.pctr.0020008     Document Type: Article

References (34)

1. HIV InSite (2006) Antiretroviral drug profiles. Available: http://hivinsite.ucsf.edu/InSite?page=ar-drugs. Accessed 31 January 2007.
2. Medline Plus (2006) Medical encyclopedia: Sexual problems overview. Available: http://www.nlm.nih.gov/medlineplus/ency/article/001951.htm. Accessed 31 January 2007.
3. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. Fourth edition, text revision (DSM IV TR). Washington (D. C.): American Psychiatric Association.
4. Collazos J, Martinez E, Mayo J, Ibarra S (2002) Sexual dysfunction in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31: 322-326.
5. Schrooten W, Colebunders R, Youle M, Molenberghs G, Dedes N, et al. (2001) Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS 15: 1019-1023.
6. Colebunders R, Moerman F, Noestlinger C (2006) Unexpected improvement of sexual dysfunction during atazanavir therapy. AIDS 20: 1209-1210.
7. Bernal E, Masia M, Padilla S, Gutierrez F (2005) Unexpected improvement of sexual dysfunction during atazanavir therapy. AIDS 19: 1440-1441.
8. Martinez E, Collazos J, Mayo J, Blanco MS (1999) Sexual dysfunction with protease inhibitors. Lancet 353: 810-811.
9. Colson AE, Keller MJ, Sax PE, Pettus PT, Platt R, et al. (2002) Male sexual dysfunction associated with antiretroviral therapy. J Acquir Immune Defic Syndr 30: 27-32.
10. Sollima S, Osio M, Muscia F, Gambaro P, Alciati A, et al. (2001) Protease inhibitors and erectile dysfunction. AIDS 15: 2331-2333.
11. Lallemand F, Salhi Y, Linard F, Giami A, Rozenbaum W (2002) Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors. J Acquir Immune Defic Syndr 30: 187-190.
12. Florence E, Schrooten W, Dreezen C, Gordillo V, Nilsson SL, et al. (2004) Prevalence and factors associated with sexual dysfunction among HIV-positive women in Europe. AIDS Care 16: 550-557.
13. Catalan J, Meadows J (2000) Sexual dysfunction in gay and bisexual men with HIV infection: Evaluation, treatment and implications. AIDS Care 12: 279-286.
14. World Health Organization (2002) Defining sexual health: Report of a technical consultation on sexual health. Available: http://www.who.int/ reproductive-health/publications/sexualhealth/defining_sh.pdf. Accessed 31 January 2007.
15. Greenhouse P (1995) A definition of sexual health. BMJ 310: 1468-1469.
16. Medical Outcomes Trust (2007) MOS-HIV Health Survey (MOS-HIV). Available: http://chipts.ucla.edu/assessment/pdf/assessments/ MOSHIV.35item.pdf. Accessed 31 January 2007.
17. EuroQol Group (2007) EQ-5D. Available: http://gs1.q4matics.com/ EuroqolPublishWeb. Accessed 31 January 2007.
18. SF-36.org (2007) SF-36 health survey. Available: http://www.sf-36.org/. Accessed 1 February 2007.
19. World Health Organization (2002) WHOQOLHIV instrument. Available: http://www.who.int/mental_health/media/en/557.pdf. Accessed 1 February 2007.
20. World Health Organization (2002) WHOQOL-100. Available: http://www.who.int/mental_health/resources/evidence_research/en/ index.html. Accessed 1 February 2007.
21. Tarlov AR, Ware JE Jr, Greenfield S, Nelson EC, Perrin E, et al. (1989) The Medical Outcomes Study. An application of methods for monitoring the results of medical care. JAMA 262: 925-930.
22. de Haan R, Aaronson N, Limburg M, Hewer RL, van Crevel H (1993) Measuring quality of life in stroke. Stroke 24: 320-327.
23. Horsman J, Furlong W, Feeny D, Torrance G (2003) The Health Utilities Index (HUI(R)): Concepts, measurement properties and applications. Health Qual Life Outcomes 1: 54.
24. Ruf M, Lovitt C, Imrie J (2006) Recreational drug use and sexual risk practice among men who have sex with men in the United Kingdom. Sex Transm Infect 82: 95-97.
25. Crosby R, Diclemente RJ (2004) Use of recreational Viagra among men having sex with men. Sex Transm Infect 80: 466-468.
26. Sanchez TH, Gallagher KM (2006) Factors associated with recent sildenafil (viagra) use among men who have sex with men in the United States. J Acquir Immune Defic Syndr 42: 95-100.
27. Eli Lilly (2005) Eli Lilly and company: Answers for shareholders. 2005 annual report, notice of 2006 annual meeting, and proxy statement. Available: http://www.lilly.com/investor/annual_report/lillyar2005.pdf. Accessed 1 February 2007.
28. Pfizer (2005) Pfizer financial report 2005. Available: http://www.pfizer.com/pfizer/annualreport/2005/financial/ financial2005.pdf. Accessed 1 February 2007.
29. Moynihan R (2003) The making of a disease: female sexual dysfunction. BMJ 326: 45-47.
30. Lexchin J (2006) Bigger and better: How Pfizer redefined erectile dysfunction. PLoS Med 3: e132. doi:10.1371/journal.pmed.0030132
31. Spindler H, Scheer S, Chen S, Klausner J, Valleroy L, et al. (2006) Viagra, methamphetamine and HIV risk: Results from a probability sample of MSM, San Francisco [abstract]. 16th International AIDS Conference; 13-18 August 2006; Toronto, Canada.
32. Nöstlinger C, Colebunders R, Uberti C, Mumelter B, Csepe P, et al. (2006) Improving sexual and reproductive health of persons living with HIV (The EUROSUPPORT V study) [abstract]. 16th International AIDS Conference; 13-18 August 2006; Toronto, Canada.
33. Trotta MP, Ammassari A, Cozzi-Lepri A, Zaccarelli M, Castelli F, et al. (2003) Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. AIDS 17: 1099-1102.
34. Wein AJ, Van Arsdalen KN (1988) Drug-induced male sexual dysfunction. Urol Clin North Am 15: 23-31.